Michael Unbehauen
CMC Lead mRNA Almirall
Michael Unbehauen brings a strong foundation in drug delivery and more than five years of experience overseeing outsourced CMC activities within the mRNA space. Prior to joining Almirall, he contributed to mRNA development efforts at BioNTech. He currently leads mRNA-related CMC activities at Almirall, helping drive innovation at the interface of development and manufacturing.
Seminars
Wednesday 22nd July 2026
Track C: Manufacturing & CMC
Wednesday 22nd July 2026
Round Table Discussion: Streamlining CDMO & Vendor Selection at GMP-Grade to Ensure Quality, Cost Effectiveness & Validation for Novel mRNA & CGT Therapies
2:10 pm
- How to evaluate and select mRNA-specialized CDMOs that align with project needs, timelines, and modality complexity?
- Establishing collaborative data-sharing and tech transfer models to ensure transparency and reduce rework
- Managing regulatory, quality and IP risks while leveraging partner strengths for faster IND or clinical production
